A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts

NCT01286441 | Completed Phase 2 Results

• 1 other identifier: VIR001-01
• Study Type: interventional
• Target: 183
• Locations: 1 country
• Sites: 20

Brief Summary

Nonclinical studies have shown sandalwood oil to have anti-inflammatory, anti-fungal, antiviral, and anti-bacterial activities. Previous clinical studies have shown East Indian Sandalwood oil to be promising as a treatment for common warts in adults and children. The primary objective of this study is to evaluate the efficacy and safety of 10%, 20%, and 30% East Indian Sandalwood Oil (EISO) ointment compared with the ointment placebo administered twice daily (bid) for 12 weeks for the treatment of common warts (Verruca vulgaris).

Conditions

Common Warts

Keywords

Verruca vulgaris

Outcome Measures

Primary Outcomes (1)

• Complete Resolution of All Treated Warts by or at Week 12

  During the Treatment Period, subjects will apply study medication to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks. Clinical evaluations, including wart counts, wart measurements and recording of adverse events and concomitant medications will be performed. Photographs of the treatment area will be taken at all study visits

  12 weeks

Secondary Outcomes (1)

• Number of Subjects Achieving Partial Resolution of Treated Warts

  12 weeks

Study Arms (4)

Placebo

PLACEBO COMPARATOR

Placebo for East Indian Sandalwood Oil ointment administered topically twice daily

Drug: Placebo

10% EISO

ACTIVE COMPARATOR

East Indian Sandalwood Oil ointment, 10% (w/w), applied topically twice daily

Drug: 10% EISO

20% EISO

ACTIVE COMPARATOR

East Indian Sandalwood Oil ointment, 20% (w/w), applied topically twice daily

Drug: 20% EISO

30% EISO

ACTIVE COMPARATOR

East Indian Sandalwood Oil ointment, 30% (w/w), applied topically twice daily

Drug: 30% EISO

Interventions

10% EISO DRUG

During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.

Also known as: 10% East Indian sandalwood oil ointment

10% EISO

Placebo DRUG

During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.

Also known as: sandalwood scented placebo ointment

Placebo

20% EISO DRUG

During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.

Also known as: 20% East Indian sandalwood oil ointment

20% EISO

30% EISO DRUG

During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.

Also known as: 30% East Indian sandalwood oil Ointment

30% EISO

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Are male or female, and 18 years of age or older at enrollment;
• Have 2 to 10 common warts (Verruca vulgaris) to be treated within a single 5 cm-by-5 cm contiguous area (the treatment area);
• The treatment area can be located anywhere on the body except for the following prohibited areas: the eye area (including eyelids), lips, mouth cavity, nasal cavity, inner ear, palms of the hands, soles of the feet, or the anogenital area;
• The total surface area of the warts to be treated is ≤600 mm2;
• If female of childbearing potential, have a negative urine pregnancy test at Screening and Randomization/Day 1, and are willing to use effective contraception during the study (ie, oral, implanted, or injectable contraceptives, intrauterine device (IUD), diaphragm, condom, tubal ligation, abstinence, or are in a monogamous relationship with a partner who has had a vasectomy);
• Are judged to be in good health based upon the results of a physical examination, medical history, and safety laboratory tests;
• Are willing and able to provide written informed consent;
• Agree to use no wart-removing product (prescription or over-the-counter \[OTC\]) other than the study product during the course of the study;
• Are willing and able to comply with the requirements of the study;
• Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of AEs.
• Are willing to refrain from using cosmetics or other topical products in the treatment area for the duration of the study.

You may not qualify if:

• Have less than 2 or more than 10 common warts within the designated treatment area;
• Have warts outside of the treatment area that would interfere with study procedures or analyses;
• Have participated in an investigational trial within 30 days prior to enrollment;
• Have participated in a prior trial investigating EISO use for the treatment of common warts;
• Have used salicylic acid or any over-the-counter wart-removing product in the treatment area within 30 days prior to enrollment;
• Have used or will use oral zinc and/or cimetidine within 30 days prior to enrollment or during the course of the study;
• Have received cryotherapy in the treatment area within 60 days prior to enrollment;
• Have required or will require systemic intake of immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days prior to enrollment or during the course of the study. Routine use of inhaled or intranasal corticosteroids during the study is allowed;
• Have any current and/or recurrent pathologically relevant skin infections in the treatment area other than common warts (with the exception of Herpes simplex virus labialis);
• Have any current uncontrolled infection;
• Are pregnant, plan to become pregnant, or are breastfeeding;
• Have a known sensitivity to any of the constituents of the investigational or control products including sandalwood oil, fragrances, or any members of the Compositae family of vascular plants (eg, sunflowers, daisies, dahlias, etc.);
• Have any chronic or acute medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk (including human immunodeficiency virus, systemic lupus erythematosis, viral hepatitis, etc.);
• Have any active malignancy or are undergoing treatment for any malignancy other than nonmelanoma skin cancer;
• Have, in the opinion of the investigator, clinically significant clinical laboratory results at the time of screening that may interfere with the study results or place the subject at undue risk.

Sponsors & Collaborators

• ViroXis Corporation: lead

Study Sites (20)

Unknown Facility

Rogers, Arkansas, 72758, United States

Location

Unknown Facility

Fremont, California, 95438, United States

Location

Unknown Facility

Lomita, California, 90717, United States

Location

Unknown Facility

Miami, Florida, 33135, United States

Location

Unknown Facility

Arlington Heights, Illinois, 60005, United States

Location

Unknown Facility

Elwood, Indiana, 46036, United States

Location

Unknown Facility

Owensboro, Kentucky, 42303, United States

Location

Unknown Facility

Beverly, Massachusetts, 01915, United States

Location

Unknown Facility

Haverhill, Massachusetts, 01830, United States

Location

Unknown Facility

Fort Gratiot, Michigan, 48059, United States

Location

Unknown Facility

Newington, New Hampshire, 03801, United States

Location

Unknown Facility

Portsmouth, New Hampshire, 03801, United States

Location

Unknown Facility

Rochester, New York, 14623, United States

Location

Unknown Facility

Raleigh, North Carolina, 27612, United States

Location

Unknown Facility

Salisbury, North Carolina, 28144, United States

Location

Unknown Facility

Columbus, Ohio, 43231, United States

Location

Unknown Facility

College Station, Texas, 77845, United States

Location

Unknown Facility

Dallas, Texas, 75234, United States

Location

Unknown Facility

San Antonio, Texas, 78258, United States

Location

Unknown Facility

Virginia Beach, Virginia, 23455, United States

Location

MeSH Terms

Conditions

Warts

Condition Hierarchy (Ancestors)

Papillomavirus Infections; DNA Virus Infections; Virus Diseases; Infections; Skin Diseases, Viral; Tumor Virus Infections; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Results Point of Contact

• Title: Dr. Paul Castella Ph.D.
• Organization: Santalis Pharmaceuticals

paulc@santalispharma.com

210-399-2316

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 27, 2011
• First Posted: January 31, 2011
• Study Start: November 1, 2012
• Primary Completion: April 1, 2014
• Study Completion: June 1, 2014
• Last Updated: May 29, 2019
• Results First Posted: May 29, 2019

Record last verified: 2019-05

Locations

US (20)